# Polygene Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/polygene-bio

- Industry: Biotechnology
- Headquarters: Beijing, China
- Latest round: Angel (Mar 20, 2026)
- Investors on record: 1

## About

Based in Beijing, China and founded in 2025, Beijing Juyin Biotechnology Co., Ltd., trading as Polygene Bio, focuses on the research and development of next-generation hyperbranched polymers, specializing in highly efficient and stable transfection reagents and gene delivery. In March 2026, Polygene Bio closed Angel funding from Beijing Capital Science and Technology Development Group Investment Management.
The company is committed to solving the pain point of traditional non-viral transfection reagents (such as liposomes and PEI) in achieving a balance between transfection efficiency and cytotoxicity, as well as the "bottleneck" problem of the long-standing monopoly of European and American companies in the domestic high-end core transfection reagent market.
The company generates revenue by doing R&D, and providing upstream core materials and gene transfection reagents and other related services.
The Angel funding raised in March 2026 will primarily be used to upgrade the company's core technology platform and construct a domestic GMP production center.

## Funding rounds

- Angel, Mar 20, 2026 — Beijing Capital Science and Technology Development Group Investment Management

## Investors

- Beijing Capital Science and Technology Development Group Investment Management (https://capitalatlas.ai/funds/beijing-capital-science-and-technology-development-group-inv) — Angel